Preventing the harm of a closer look: Contrast-induced nephropathy in adults

Orthopedics

Volumn 35, Issue 4, 2012, Pages 298-303

  Holder, Martina C ^a   Lewis, Daniel A ^a   Shane Winstead, P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; IONIC CONTRAST MEDIUM;

ADULT; AGE; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DEHYDRATION; DIABETES MELLITUS; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; INTRAVENOUS ADMINISTRATION; KIDNEY FAILURE; NEPHROTOXICITY; NONHUMAN; OSMOLARITY; PATHOPHYSIOLOGY; PROGNOSIS; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SERUM OSMOLALITY; UNSPECIFIED SIDE EFFECT;

ADULT; CONTRAST MEDIA; HUMANS; IODINE; KIDNEY DISEASES;

EID: 84860669138     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20120327-06     Document Type: Article

References (39)

1. Kagen A, Sheikh-Hamad D. Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies. Clin Cardiol. 2010;33(2):62-66.
2. American Society of Health-System Pharmacists. Quick Guide to Contrast Media. Bethesda, MD: Contrast Media and Medication Management Standard Resource Center; 2010.
3. ACR Committee on Drugs and Contrast Media. ARC Manual on Contrast Media-Version 7:2010. http://www.acr.org/secondary MainMenuCategories/quality- safety/contrast-manual.aspx. Accessed March 26, 2012.
4. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212-218. (Pubitemid 38235157)
5. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799-1806. (Pubitemid 43958473)
6. Massicotte A. Contrast mediuminduced nephropathy: strategies for prevention. Pharmacotherapy. 2008;28(9):1140-1150.
7. Mehran R, Nikolsky E. Contrastinduced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006; (100): S11-S15.
8. Tumlin J, Stacul F, Adam A, et al; for the CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy [published online ahead of print February 17, 2006]. Am J Cardiol. 2006;98(6 A):14K-20K.
9. Nygren A. Contrast media and regional renal blood flow: a study of the effects of ionic and non-ionic monomeric and dimeric contrast media in the rat. Acta Radiol Suppl. 1992;37(pt 3):123-135.
10. Ribeiro L, De Assuncao e Silva F, Kurihara RS, Schor N, Mieko E, Higa S. Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int. 2004;65(2):589-596. (Pubitemid 38130653)
11. Sancak A, Derici U, Arinsoy T, Erbas D, Uenlue M, Hasanoglu E. Effects of contrast media on endothelin and nitric oxide system after computed tomography. Gazi Med J. 2002;13:81-85. (Pubitemid 35334178)
12. Elias M, Swae'ed S, Shneor A, et al. Serum antioxidant capacity and the risk of contrast medium nephropathy. Nephron Clin Prac. 2005;99(1):c13-c17.
13. Persson PB, Hansell P, Liss P. Pahtophysiology of contrast medium-induced nephropathy. Kidney Int. 2005;68(1):14-22.
14. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930-936. (Pubitemid 34454211)
15. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital acquired renal insufficiency: a prospective study. Am J Med. 1983;74(2):243-248. (Pubitemid 13192180)
16. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275:1489-1494. (Pubitemid 26140761)
17. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the Iohexol Cooperative Study. Kidney Int. 1995;47(1):254-261.
18. Barrett BJ, Carlisle EF. Metaanalysis of the relative nephrotoxicity of high-and low-osmolality iodinated contrast media. Radiology. 1993;188(1):171-178. (Pubitemid 23183119)
19. Aspelin P, Aubry P, Fransson SG, Strasser R, Wellenbrock R, Berg KJ; for the NEPHRIC Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6):491-499. (Pubitemid 36159884)
20. Hardiek K, Katholi R, Ogden C, Pianfetti L. Double blind, randomized comparison of iopamidol 370 and iodixanol 320: renal response in diabetic subjects. in: Radiological Society of North America Scientific Assembly and Annual Meeting Program. Oak Brook, IL: Radiological Society of North America, 2003:541.
21. Jo SH, Youn TJ, Park JS, Koo BK, Kang HJ. Iodixanol is less nephrotoxic than ioxaglate in patients with renal insufficiency after coronary angiography [abstract]. J Am Coll Cardiol. 2005;45(suppl 1):A31.
22. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 2005;68(5):2256-2263. (Pubitemid 43117802)
23. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barret B. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J. 2007;58(2):79-87. (Pubitemid 46607524)
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
25. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470. (Pubitemid 29135798)
26. McCullough P, Adam A, Becker C, et al. Risk prediction of contrast-induced nephropathy [published online ahead of print February 13, 2006]. Am J Cardiol. 2006;98(6A):27K-36K.
27. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005;67(2):706-713. (Pubitemid 40139864)
28. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90(10):1068-1073. (Pubitemid 35335595)
29. Abujudeh HH, Gee MS, Kaewlai R. In emergency situations, should serum creatinine be checked in all patients before performing second contrast CT examinations within 24 hours? J Am Coll Radiol. 2009;6(4):268-273.
30. Trivedi H, Foley WD. Contrastinduced nephropathy after a second contrast exposure. Ren Fail. 2010;32(7):796-801
31. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrastinduced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328-2334 (Pubitemid 38656299)
32. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast mediuminduced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038- 1046.
33. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast inducedacute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1584-1592
34. Tepel M, van der GM, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographiccontrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-184 (Pubitemid 30489215)
35. Pannu N, Tonelli M. Strategies to reduce the risk of contrast nephropathy: an evidency-based approach. Curr Opin Nephrol Hypertens. 2006;15:285-290.
36. Baker CS, Wragg A, Kumar S, De PR, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41(12):2114-2118. (Pubitemid 36724254)
37. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773-2782. (Pubitemid 43974195)
38. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55(20):2201-2209.
39. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med. 2006;166(2):161-166. (Pubitemid 43144938)